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Biodistribution and Kinetics of Radiolabeled 
Proteins in Rats with Focal Infection
Wim J.G. Oyen, Roland A.M.J. Claessens, Jos W.M. van der Meer, and Frans H.M. Corstens
Departments o f  Nuclear Medicine and Internal Medicine, University Hospital Nijmegen, and Division of General Internal 
Medicine, Nijmegen, The Netherlands
The purpose of this study was to evaluate the role of both 
protein and radionuclide in the accumulation of 111 In-labeled 
human immunoglobulin G (IgG) in infectious foci. In rats with 
a calf muscle infection, biodistribution was determined 2 , 6 , 
24, and 48 hr after injection of a radiopharmaceutical. For 
IgG, human serum albumin (HSA) and human immunoglobulin 
A (IgA), all labeled with 111ln, target-to-background (T/B) ratios 
were similar throughout the study. However, absolute ab­
scess uptake of 111ln-lgA was significantly lower. For IgG 
labeled with 1111n, 123l, or 99mTc, similar T/B ratios were found 
up to 24 hr. After 48 hr, the T/B ratio of 1111n-IgG was 
significantly higher than the T/B ratio of 123l-lgG. The absolute 
abscess uptake of 1111n-IgG was higher than that of 99mTc- 
IgG at 24 hr and 123l-lgG at 48 hr. In conclusion, the radio­
nuclide appears to be of major importance in the accumulation 
of radiolabeled proteins in infectious foci. Protein mainly influ­
ences blood clearance and distribution in organs. The Fc-7 
receptor is not crucial for accumulation in infectious foci.
J Nucl Med 1992; 33:388-394
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k-/everal reports suggest the utility of scintigraphy with 
11'In-labeled nonspecific polyclonal human immunoglob­
ulin G (m In-IgG) for the detection of various types of 
focal infection in humans ( 1-4). However, the mechanism 
of 11 'In-IgG accumulation in infectious and noninfectious 
inflammatory foci is not fully understood. Both specific 
receptor interaction and nonspecific macromolecular en­
trapment have been proposed (5-8). To evaluate the role 
of the type of protein in the mechanism of 11‘In-IgG 
accumulation in infectious foci, 11'In-IgG was compared 
to "'In-labeled human serum albumin (HSA), and '"In­
labeled human immunoglobulin A (IgA); also 123I-IgG was 
compared to 13II-HSA. To elucidate the role o f the radio­
nuclide and corresponding labeling method, IgG was la­
beled with '"In, l23I and ygmTc and HSA was radiolabeled 
with "'In and ,3,I.
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MATERIALS AND METHODS 
Radiopharmaceuticals
The biodistribution and kinetics of six radiolabeled proteins 
were studied.
Indium-111-IgG. (IgG: Sandoglobulin, Sandoz AG, Nuern­
berg, FRG). Diethylenetriaminepentaacetic bicyclic anhydride 
(bicyclic DTPA) was conjugated to the protein according to 
Hnatowich and colleagues (9). The number of DTPA ligands, 
conjugated to one protein molecule was determined by the 
method described by Hnatowich et al. (9). The purified DTPA- 
conjugated protein was diluted to 2 mg/ml with 0.15 M  acetate 
(pH = 6.5) and sterilized by membrane filtration. Aliquots of 0.5 
ml of the conjugate were radiolabeled with 11 'In (Indium chloride, 
Amersham International Ltd., Buckinghamshire, UK) via citrate 
transchelation. The radiochemical purity of all radiopharmaceu­
ticals was determined by instant thin-layer chromatography 
(ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, Ann 
Arbor, MI) with 0.1 M citrate (pH = 5) as solvent. Labeling 
efficiency was checked batchwise by HPLC on an l25I size exclu­
sion column (Waters-Millipore) with a 0.1 M  acetate buffer 
(pH = 6) as solvent. A dose of 10 Mg< labeled with 2 MBq 11‘In, 
was injected intravenously.
Iodine-123-IgG. (IgG: Sandoglobulin, Sandoz AG, Nuernberg, 
FRG). IgG was labeled with ,23I by means of the Iodo-gen method 
(Iodo-gen, 28600, Pierce, Rockford, IL) {10). Unbound iodine 
was removed with Sephadex 25. A dose of 10 jug IgG labeled with
3 MBq l23I was injected intravenously.
Technetium-99m-IgG. Kits for labeling IgG with ',gmTc (Tech- 
nescan-HIG) were kindly provided by Mallinkcrodt Diagnostica 
Holland, Petten, The Netherlands. A kit, containing 1 mg of 2- 
iminothiolane-derivatized IgG (obtained from the Central Labo­
ratory of the Bloodtransfusion Service of The Netherlands Red 
Cross, Amsterdam, The Netherlands) and stannous chloride, was 
radiolabeled with 500 MBq 99mTc eluate. In vitro stability was 
tested by HPLC analysis after in-vitro storage of ggmTc-IgG at 
37°C for 24 hr. A dose of 10 ^g, labeled with 4 MBq l,9mTc, was 
injected intravenously.
Indium-111-HSA. (Human Albumin 20%, Central Laboratory 
of the Bloodtransfusion Service of The Netherlands Red Cross, 
Amsterdam, The Netherlands). DTPA-conjugation and '" In  
labeling were accomplished as described above. A dose of 10 jug, 
labeled with 2 MBq 11‘In, was injected intravenously.
Iodine-131-HSA. (Medgenix Diagnostics, Fleurus, Belgium). 
The radiopharmaceutical was obtained commercially. The pro­
tein bound 1311 activity was 96%. A dose of 40 Mg labeled with
0.5 MBq 1311 was administered intravenously.
Indium-111-IgA. (Human IgA, 11010, Sigma Chemical Com­
pany, St. Louis, MO). DTPA-conjugation and 11‘In labeling were
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accomplished as described above. IgA activity was determined 
before and after conjugation with DTPA by immunoelectropho- 
resis. Non-IgA bound ‘"In was removed with Sephadex PD 10. 
A dose of 10 ng, labeled with 2 MBq '" In ,  was injected intrave­
nously.
Animals and Study Design
A calf muscle abscess was induced in young, male, randomly 
bred Wistar rats (weight 200-220 g) after ether anesthesia with 
approximately 2 x  108 colony-forming units of Staphylococcus 
aureus in 0.1 ml 50:50% suspension of autologous blood and 
normal saline. The animals were randomly divided in groups.
Twenty-four hours after the inoculation of Staphylococcus 
aureus in the muscle, when swelling of the muscle was apparent, 
the respective radiopharmaceuticals were injected in the tail vein.
To collect tissues, rats were killed with 30 mg intraperitoneally 
injected phenobarbital, followed by cervical dislocation at 2 , 6 ,
24, and 48 hr after injection. For WmTc-IgG, tissues were obtained 
up to 24 hr p.i. Each peptide was evaluated in six animals at each 
time point. Samples of bone marrow (taken from the right femur), 
blood, and urine were collected. The infected left calf muscle, the 
right calf muscle, the liver, the spleen, the kidneys, and the right 
femur were collected and blotted dry. The activity in the tissues 
and samples was measured in a shielded well-type gamma coun­
ter. The excreted activity in feces and urine of each peptide at 
each time point between injection of the radiopharmaceutical 
and killing of the animals was also measured in the well counter. 
To correct for radioactive decay and permit calculation of the 
uptake of the radiopharmaceuticals in each organ as a fraction of 
the injected dose, aliquots of the respective doses were counted 
simultaneously. The measured activity in tissues and samples was 
expressed as percentage of injected dose per gram (%ID/g) and 
the excreted activity per animal as percentage of total dose 
administered.
For calculation of background activity, we used a combination 
of normal muscle activity and blood activity. Since the blood 
volume of rats approximates 60 ml per kg bodyweight (6 %), 
94% x  the activity per gram in muscle plus 6 % x the activity per 
gram in blood was adopted as the value for background activity 
(77). Abscess-to-background ratios were calculated.
Statistical Analysis.
All mean values are given ±  s.e.m. Statistical analysis was 
performed using Tukey’s analysis of variance. The level of signif­
icance was set at 0.05.
RESULTS
Labeling Effiency and Characterization of Proteins
Conjugation of DTPA to proteins resulted in two to 
three DTPA ligands per protein molecule. For "'In-IgG, 
labeling efficiency was 95%. ITLC and HPLC analysis 
results were similar. In patients, all ‘"In activity in blood 
samples was still protein-bound at 48 hr p.i. No cell 
binding of " 'In could be detected.
For l23I-IgG, radiochemical purity was 98% after re­
moving unbound iodine. Forl)l)mTc-IgG, labeling efficiency 
was 99%. HPLC analysis showed that approximately 75% 
of the original l)9mTc activity was still protein-bound after 
24 hr in vitro.
For "'In-HSA and 13II-HSA, the protein bound activity 
was 99% and 96%, respectively.
IgA activity after conjugation with DTPA was 89% of 
the original activity. Indium-111-IgA labeling efficiency 
was 96% after purification.
Role of Protein
Comparison o f  In -lll-IgG , In -ll l-H S A  and In-111- 
IgA. Figure 1 shows that all radiopharmaceuticals had a 
higher accumulation in the infectious focus than in the 
contralateral normal muscle at all sampling times. Indium- 
1 1 1-IgG uptake in the abscesses remained at a constant, 
high level. Although not significant, both '"In-HSA and 
'"In-IgA showed a tendency to decrease over time. The 
uptake of ‘"In-IgG and '"In-HSA in the abscess revealed 
no significant differences. Indium-111-IgA uptake was sig­
nificantly lower at all points in time (p <  0.05;. However, 
abscess-to-background ratios of all "'In-labeled proteins 
(Fig. 2) did not differ significantly.
FIGURE 1. Activity uptake 
in abscess and muscle, ex­
pressed as %dose/g (error 
bars indicate s.e.m.).
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FIGURE 2. Abscess  to 
background ratios (error bars 
indicate s.e.m.).
O
h-
<
a:
Q
6
5
Z)
O
DC
0
*  3 
O 
<
CD
CD 2
CO
LLIo
CD3 1
0
99 2 h p.i. 6 h p.i. 24 h p.i. N
\
N
X
XJV  i
\ i
r i  ’ Vr « I * ■ Li
.* mMW
t,
THjfl
V
UlYTTl
; Ì
M
¿iiul
48 h p.i.
IML!<5*d
rad;
H,145
filBR
s
VN \
v SX
\
\ N \
\ N, \  I
q 1
X^ NI
X N
Ut—n r
\v 1 
\
\
\
XI
\
TI
* A
\
\ 1  .
V |N
X
N
X
\
ln-111-lgG 1-123-lgG Tc-99m-lgG ln-111-HSA l-131-HSA ln-111-IgA
After 6 hr, lMIn-IgG cleared significantly slower from 
the blood than m In-HSA, p <  0.05 (Fig. 3). The blood 
concentration of lMIn-IgA was significantly lower than 
that of " 'In-IgG and MlIn-HSA at each time point 
(p <  0.05).
Table 1 and Figure 4 show the distribution in various 
organs. Indium-111 -IgA showed marked accumulation in 
the kidneys, liver and spleen. Indium-1 1 1-IgG and IMIn- 
HSA uptake in the liver and the spleen did not differ 
significantly. However, renal uptake of 11'In-IgG was sig­
nificantly higher compared to 11 'In-HSA (p <  0.05).
Excretion of 11'In-IgG and 11'In-HSA were also similar 
(Fig. 5). Indium-11 1 -IgA excretion was slightly higher.
Comparison o f ' 2'I-IgG and  1311-HSA. At 24 and 48 hr, 
both l23I-IgG and 13II-HSA revealed significant washout 
from the abscess, p <  0.05 (Fig. 1). The absolute abscess 
uptake of l23I-IgG was significantly higher than the corre­
sponding uptake of l31I-HSA at 24 and 48 hr, since the 
washout of l23I-IgG was slower than that of l31I-HSA (p <  
0.05). This also applied for the absolute muscle uptake. 
For this reason, abscess-to-background ratios of the two 
iodinated proteins did not differ (Fig. 2).
FIGURE 3. Blood activity, 
expressed as %dose/g (error 
bars indicate s.e.m.).
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TABLE 1
Biodistribution, Expressed as Percentage of Administered Dose per Gram (Mean Values ±  s.e.m.)
Organ Time 1111n-IgG 123l-lgG 99mT c-IgG 111ln-HSA 131I-HSA 1111n-lgA
Liver 2 1.14 ± 0.03 0.92 ±  0.11 0.88 ± 0.03 1.07 ±  0.16 0.54 ± 0.04 6.25 ±  0.12
6 1.32 ± 0.07 0.66 ± 0.10 0.77 ± 0.07 1.39 ± 0.19 0.42 ± 0.02 6.94 ±  0.34
24 1.37 ± 0.09 0.26 ± 0.02 0.38 ± 0.08 1.29 ±  0.19 0.12 ±  0.00 5.94 ±  0.19
48 1.49 ±  0.04 0.29 ± 0.03 ---------- 1.47 ±  0.21 0.05 ± 0.01 4.85 ±  0.33
Spleen 2 1.09 ± 0.04 0.90 ± 0.10 0.88 ± 0.08 1.12 ± 0.13 0.58 ± 0.05 4.77 ± 0.59
6 1.43 ± 0.10 0.72 ±  0.08 0.77 ± 0.08 1.68 ±  0.15 0.44 ± 0.03 3.70 ± 0.36
24 1.61 ± 0.09 0.36 ± 0.02 0.40 ±  0.02 1.90 ±  0.31 0.12 ± 0.01 4.41 ±  0.60
48 1.81 ±  0.11 0.28 ± 0.02 ---------- 2.14 ± 0.19 0.05 ±  0.00 3.15 ±  0.48
Kidneys 2 4.18 ±  0.22 1.47 ± 0.14 9.41 ±  0.84 1.57 ±  0.17 0.93 ± 0.09 7.64 ± 0.20
6 5.45 ± 0.49 1.15 ±  0.08 11.10 ±  0.96 1.62 ±  0.15 0.70 ± 0.03 7.88 ± 0.13
24 5.38 ± 0.46 0.56 ± 0.03 10.15 ± 0.81 1.74 ± 0.18 0.21 ±  0.01 8.27 ± 0.14
48 5.36 ±  0.61 0.45 ± 0.03 --------- 2.50 ± 0.31 0.09 ± 0.01 7.81 ±  0.25
Bone marrow 2 1.01 ± 0.10 1.30 ± 0.10 1.27 ±  0.28 1.19 ± 0.07 0.90 ± 0.17 1.14 ±  0.08
6 1.45 ±  0.08 0.99 ±  0.11 0.78 ±  0.09 1.13 ± 0.18 0.68 ± 0.05 0.99 ± 0.06
24 1.40 ±  0.08 0.40 ± 0.03 0.27 ±  0.01 1.24 ± 0.02 0.20 ± 0.05 0.89 ± 0.07
48 1.40 ± 0.08 0.39 ± 0.02 ---------- 1.07 ±  0.10 0.06 ± 0.01 0.79 ± 0.09
Bone 2 0.25 ±  0.02 0.27 ± 0.02 0.22 ±  0.03 0.28 ± 0.04 0.24 ± 0.02 0.18 ±0 .02
6 0.23 ±  0.02 0.23 ±  0.02 0.16 ±  0.01 0.37 ±  0.04 0.18 ± 0.03 0.14 ± 0.01
24 0.28 ±  0.02 0.11 ±  0.01 0.08 ± 0.00 0.39 ±  0.05 0.10 ± 0.01 0.16 ±0 .02
48 0.34 ±  0.05 0.10 ±  0.01 ---------- 0.47 ±  0.09 0.08 ± 0.00 0.11 ±  0.01
The blood clearance and excretion rate o f l23I-IgG were 
significantly slower than the clearance and excretion rate 
of l3'I-HSA p <  0.05 (Fig. 3 and 5). The accumulation in 
organs was significantly lower for l3'I-HSA than for l23I- 
IgG, p <  0.05 (Table l and Fig. 4).
Role of Radionuclide
Comparison o f  m In-IgG, l2}I-IgG, and 99mTc-IgG. As 
shown in Figure 1, absolute abscess uptake over time 
showed different patterns for these labels: 11'In-IgG was 
relatively high and constant from 6  hr p.i. onwards; l23I- 
IgG was also high at 6  hr p.i., but decreased afterwards; 
qymTc-IgG was relatively low and decreased between 6  and
24 hr p.i. The uptake of " ‘In-IgG in the abscess was 
significantly higher than that o f 99mTc-IgG at 24 hr (p <  
0.05). Also, at 48 hr there was more " ‘In-IgG than l23I- 
IgG activity in the abscess (p <  0.05). Abscess uptake of 
l23I-IgG was initially significantly higher than that o f 99mTc- 
IgG (p <  0.05), but did not differ significantly at 24 hr p.i. 
With regard to the abscess-to-background ratios (Fig. 2), 
only the higher ratio at 48 hr p.i. of '"In-IgG compared 
to the ratio of l23I-IgG reached a level of significance
(p <  0.05).
As shown in Figure 3, significant differences could be 
noted in blood clearance: 99mTc-IgG showed the fastest 
clearance (p <  0.05) and l23I-IgG the slowest (p <  0.05).
FIGURE 4. Biodistribution 
in liver, kidney, and spleen.
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FIGURE 5. Cumulative ex­
cretion of activity, expressed 
as %dose.
The accumulation of the three IgG preparations in the 
kidneys varied significantly: l23I-IgG had the lowest (p <  
0.05) and 99mTc-IgG had the highest uptake (p <  0.05) 
(Table 1 and Figure 4). In liver, spleen, bone and bone 
marrow, m In-IgG uptake significantly exceeded 123I-IgG 
and 99mTc-IgG uptake (p <  0.05). Indium-1 1 1-IgG showed 
stable or increasing activity over time in liver, spleen, 
kidneys, bone marrow and bone. Iodine-123-IgG activity 
decreased in these organs, while 99mTc-IgG activity also 
decreased in these organs with the exception of the kidneys, 
whose activity remained relatively stable. Typically, the 
bone marrow uptake exceeded the bone uptake by a factor 
four to five for all preparations.
As shown in Figure 5, approximately 20% of the admin­
istered m In-IgG was excreted in faeces and urine within 
48 hr, excretion of l23I-IgG was higher (approximately 
30%). After administration of 99mTc-IgG approximately 
60% of the radiopharmaceutical was excreted within 24 
hr.
Comparison o f inIn-HSA and ]y'I-HSA. Similar differ­
ences as noted between m In-IgG and 123I-IgG were found 
between m In-HSA and 131I-HSA: retention in the abscess, 
constant abscess to background ratios over time, signifi­
cant accumulation in organs, and low excretion rate of  
m In-HSA versus washout from the abscess, over time 
decreasing abscess-to-background ratios, low organ up­
take, and high excretion rate of l3‘I-HSA.
DISCUSSION
The similar abscess uptake and abscess to background 
ratios of m In-IgG and IMIn-HSA at various time points 
indicate that specific receptor binding of labeled IgG in an 
infectious focus, if at all present, is not the major factor in 
accumulation of labeled IgG in such a focus, since HSA 
lacks this receptor affinity. These findings are in concert
with the autoradiographic studies by Morrel et al. and our 
own experience in neutropenic patients (7,8).
IgA is an immunoglobulin without Fc- 7  receptor affin­
ity. On inflammatory cells few Fc-a receptors are present 
(12).  However, target-to-background ratios o f m In-IgA in 
infections in extremities do not differ from those after 
m In-IgG injection, thus confirming that Fc- 7  receptor 
interaction is not a major factor in the accumulation of 
m In-IgG in infectious foci. The different uptake in liver, 
spleen and kidney of 11 'In-IgG and 11 ‘In-IgA revealed that 
protein is also a major factor in biodistribution. Since 
hepatocytes of rats are equipped with IgA receptors, the 
high liver uptake of 11'In-IgA in our experiment is not 
surprising (13).  The initially high and persistent organ 
uptake of 11‘In-IgA is in accordance with fast clearance 
from the blood to the organs. Hepatic, renal and splenic 
uptake of "'In-IgA are so high, that, at least in rats, this 
agent is not suited for imaging infectious foci in these 
areas. The differences observed between ‘"In-IgG and 
111 In-IgA confirm the results of Fischman et al., who noted 
that physical chemical differences between " ‘In-labeled 
Fab and Fc fragments o f IgG might account for differences 
in abscess localization and biodistribution (14).
More striking differences were observed with regard to 
the biological behavior of IgG when it was labeled to either 
'"In, l23I or 99mTc. Indium-111-IgG was retained in the 
abscess, while 123I-IgG and 99mTc-IgG showed washout. 
The physiological uptake in organs o f 1 "In-IgG, the radio­
pharmaceutical thus far most frequently used in patient 
studies, is relatively high for most organs, compared to 
123I-IgG and, except for kidney uptake, 99mTc-IgG.
The relatively slow blood clearance of l23I-IgG might 
appear disadvantageous in detection of infectious foci, 
because of persistingly high background activity. The most 
probable explanation for this persisting blood activity is
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dehalogenation of the protein in organs and subsequent 
washin of iodine and iodinated fragments into the circu­
lation. A labeling procedure with more stable halogenation 
could overcome both this problem as well as washout of  
iodinated IgG from the infectious focus over time. The 
low physiological uptake in organs o f 123I-IgG could be 
useful for the evaluation of infectious foci in parenchy­
matous organs. Clinical studies with "'In-IgG showed 
disappointing results for the detection of infectious foci in 
these organs (4,8).  Additional advantages of l23I are its 
physical properties: a half-life o f 13 hr which permits 
imaging up to 48 hr after administration, a relatively low 
radiation burden per unit activity compared to 11'In, thus 
allowing a higher dose to administer leading to high quality 
imaging with reasonable imaging times. A somatic dose 
equivalent of 15 mSv after injection of 75 MBq "'In-IgG 
necessitates reluctancy in the use o f this radiopharmaceu­
tical in pediatric patients (15).  The more favorable distri­
bution of 123I-IgG in this animal study compared to '“ In- 
IgG might bring IgG scintigraphy in scope for imaging of  
infection in children. Major drawbacks for widespread use 
of 123I-IgG are o f course its limited availability and high 
cost.
Technetium-99m-IgG performs well up to 6  hr p.i. 
Although the abscess-to-background ratio remained at the 
same high level after 24 hr p.i., a rapid decrease of abscess 
activity was apparent. This decrease in combination with 
a physical half-life o f 6  hr is a major impediment to 
obtaining good quality images after 24 hr. One might 
wonder whether or not this decrease makes 99mTc-IgG 
scintigraphy less suited for the detection of subacute and 
low-grade infections in humans, in whom 48-hr images 
are often necessary to achieve good sensitivity (3). The 
high renal uptake and excretion of 99mTc-IgG, which was 
also observed by Rubin et al. for 99mTc-HSA, may interfere 
with abdominal imaging (76). Nevertheless, first results in 
humans with 99mTc-IgG, using the type of kit as in the 
present study, were encouraging (77). However, the design 
of the study by Buscombe was not ideal because o f coin­
jection of 99mTc-IgG and '"In leukocytes, leading possible 
interference o f "'In photons in the late 99mTc images. 
Moreover, "'In-leukocyte scintigraphy was used as the 
golden standard. In a recent comparative study between 
‘"In-IgG and " ‘In-labeled leukocyte scintigraphy, we 
found that in certain types o f infection '"In-labeled leu­
kocyte scintigraphy was not suited as the golden standard 
(4). Recently, Abrams et al. reported a new 99mTc labeling 
method of proteins, using nicotinyl hydrazine derivative 
IgG (18).  These investigators observed equivalent biodis­
tribution of the 99mTc-labeled IgG preparation and '"In- 
IgG. The fact that 99mTc-labeled nicotinyl hydrazine deriv­
ative IgG showed no washout from the abscess is o f major 
importance for adequate imaging o f acute infection with 
99mTc-IgG. Further studies are needed to establish whether 
or not imaging up to 24 hr is sufficient to adequately reveal 
subacute and low-grade infection in humans.
Both the present study and data in the literature stress 
the relevance of the radiolabel on the dynamic distribution 
of the protein. In the present study, great similarity was 
observed between '"In-IgG and '"In-HSA. Although 
washout of l23I-IgG from the abscess was slower than that 
of 13II-HSA, both iodinated proteins showed similar trends 
with regard to uptake and retention in the abscess and the 
organs and the abscess-to-background ratios and distribu­
tion. In contrast, Calame et al. observed lower abscess-to- 
background ratios for 99mTc-HSA than for HSA-IgG (79). 
However, their experimental model differed from ours 
with regard to the animal, the strain of bacteria and 
amount of bacteria injected.
In conclusion, both the radionuclide and the protein are 
important in the biodistribution and kinetics o f radiola­
beled proteins used for detection of infectious foci. For 
accumulation in infectious foci, the radionuclide appears 
to be the major determinant. Specific Fc- 7  receptor bind­
ing is probably of minor, if any, importance in the uptake 
of radiolabeled proteins in infectious foci. Most probably 
accumulation in these areas is caused by increased vascular 
permeability initially and retention with time by macro- 
molecular entrapment. The protein defines the blood 
clearance and the distribution in organs o f radiolabeled 
proteins, thus determining the amount o f labeled protein 
that is available for delivery to an infectious focus.
Given the similarity o f "'In-IgG and '"In-HSA in this 
animal model, further studies in humans with '"In-HSA 
would be useful. Despite economic and logistic disadvan­
tages, 123I-IgG also merits further investigation. The pres­
ent study warrants further studies to develop a radiolabeled 
protein with persistingly high abscess uptake, low back­
ground activity, fast blood clearance and low physiological 
organ uptake (20).
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EDITORIAL
Targeted Proteins for Diagnostic Imaging: Does Chemistry 
Make a Difference?
The imaging of occult infection is an important area of nuclear 
medicine. Vehicles for abscess local­
ization have ranged from i,7Ga-citrate 
to radiolabeled leukocytes to radiola­
beled immunoglobulin G (IgG) of 
current interest. Although 11'In la­
beled polyclonal IgG is probably the 
most widely cited protein being eval­
uated for focal infection scintigraphy 
(1-4),  the mechanism of radiolabel 
accumulation remains unclear (5-8).  
In this issue of The Journal o f  Nuclear 
Medicine, Oyen et al. examined the 
roles of protein carrier and radiolabel 
in targeting of abscesses (9). They 
evaluated three different protein car­
riers and went on to assess the contri­
bution of three different radiolabels 
and their associated chemistries in im­
aging experimental infectious foci in 
a rat model.
In the first part of the study, the 
authors compared radiolabeled IgG 
with immunoglobulin A (IgA) and hu­
man serum albumin (HSA) controls
Received Dec. 10, 1991; accepted Dec. 12, 1991.
For reprints contact: Alan Fritzberg, NeoRx 
Corp., Seattle, WA 98119.
since these proteins lack specificity for 
abscess. In each case 11'In labeling via 
a bifunctional chelate served as the 
standard radiolabel so that localiza­
tion differences could be ascribed to 
individual protein distribution prop­
erties. Layered upon the targeting 
properties of the protein was the con­
tribution of the radiolabels and their 
chemistries. In the second part of the 
study, the authors compared various 
radiolabels with IgG serving as the 
standard protein vehicle.
This study was well-conceived and 
designed to determine the role of pro­
tein carrier and radiolabel. However, 
an accurate interpretion of the role of 
the protein assumes the radiolabel 
serves as a radiotracer. Furthermore, 
an interpretion of the role of the ra­
diolabel requires an analysis o f its 
chemistry and an appreciation for the 
pharmacokinetics of its radioactive 
metabolites. Since these properties di­
rect the biodistribution of radioactiv­
ity, it is instructive to briefly review 
relevant factors such as attachment 
stability, metabolic fate, and route of 
excretion characteristic of radioio­
dines, "'In and l,9mTc as used in this 
study.
IODINE AS RADIOTRACER
Radioiodine isotopes continue to 
be the most widely used protein radio­
labels: l23I for imaging, and l25I and 
13II for preclinical studies with their 
convenient longer half-lives and ready 
availability. The “easy” direct radioi- 
odination approach in which the ra­
dioiodine is added to the activated 
ortho position of tyrosine is most 
often used, as was done in the Oyen 
et al. study (9). Label stability is usu­
ally sufficient to follow proteins in 
circulation or bound to cell surfaces. 
Once internalized by cells, however, 
catabolism releases peptide fragments 
or free amino acids with further met­
abolic processing ultimately releasing 
radioiodide (10).  Deiodination may 
occur rapidly as in the example of the 
T-101 antibody in which imaging of 
cutaneous T-cell lymphoma is vir­
tually precluded by rapid loss of radio­
activity from tumor cells (77). Meta- 
bolically stabilized ligand chemistry 
has been developed which substan-
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